Global EZH2 Inhibitors Market Research Report: Forecast (2023-2030)

Market Definition

EZH2 (Enhancer of the Zeste Homolog 2) gene is responsible for the production of histone methyltransferase enzymes, which causes the methylation of histones and subsequent suppression of downstream genes. This suppression activity forms a crucial part of cell fate determination. The EZH2 gene has been validated across various studies to suppress the growth of cancer cells.

Market Insights & Analysis: Global EZH2 Inhibitors Market (2023-30):

The Global EZH2 Inhibitors Market is projected to grow at a CAGR of around 25.85% during the forecast period, i.e., 2023-30. It owes to increasing R&D investments by biotechnology companies and government institutions in developing new therapies to address the escalating number of cancer patients worldwide. EZH2 inhibitors are regarded as promising cancer treatment drugs, which is a result of ongoing clinical trials and research to explore their potential as a novel target therapy for cancer treatment. Hence, with a rise in healthcare spending for cancer & related treatments, EZH2 inhibitors are anticipated to witness high demand in the coming years.

• According to the National Health Expenditure data, the US healthcare spending grew 2.7% to around USD 4.3 Trillion in 2021, or USD 12,914 per person, and accounted for 18.3% of the Gross Domestic Product (GDP).

With the advent of next-generation sequencing, many molecular alterations & sequences of cancer have been identified. These alterations of DNA methylation and histone modification have led to the protein that can change the structure of DNA and other molecules, which can affect gene expressions. These changes in gene structure help in the development of cancer progression drugs and, in turn, positively impact market growth. Moreover, the implication of EZH2 drugs in various malignant tumors like prostate, breast, & pancreas, among others, is anticipated to increase its use among cancer-diagnosed patients.

Apart from this, the increasing acceptance & approval of these drugs in various geographies like Japan, China, etc., and the continuous development of these drugs for advanced alteration, would further aid the growth of the Global EZH2 Inhibitors Market in the forecast years.

Global EZH2 Inhibitors Market Driver:

Globally Rising Number of Cancer Patients: Globally, the cancer patient population has been growing at a rapid pace, backed by the rise in cancer-causing chemicals in the environment and the increased penetration of natural UV radiation. Consequently, there's a surging need for accurate & convenient diagnostic systems for the early detection of cancer, i.e., instigating the demand for developing EZH2 inhibitors, which have a favorable safety profile and a promising immunogenic potential. EZH2 inhibitors hold the potential to enhance the efficacy of cancer treatment, especially for patients with lung & prostate cancer, in which specific target drugs are used. Hence, increased investments by governments & pharmaceutical companies in R&D for new cancer treatments are anticipated to drive the Global EZH2 Inhibitors Market in the coming years.

Global EZH2 Inhibitors Market Opportunity:

Rising Awareness About Personalized Drugs: Personalized drugs rely on the identification of specific biomarkers that can help identify patients who are most likely to benefit from EZH2 inhibitors. By testing for mutations in the EZH2 gene, doctors can determine which patients are likely to respond to treatment with EZH2 inhibitors. These drugs can improve the efficacy of cancer treatment by targeting the cancer cells more precisely, leading to better patient outcomes, such as longer survival times and improved life quality. In addition, they can reduce the side effects of cancer treatment by avoiding damage to healthy cells, making the overall treatment more tolerable for patients.

Various research organizations, such as the National Institute of Health, are working closely with drug development companies like Roche, Pfizer, etc., to develop personalized medicine for cancer treatment. Hence, as more biomarkers are discovered & validated, it will create promising opportunities for the growth of the Global EZH2 Market in the coming years.

Global EZH2 Inhibitors Market Challenge:

Stringent Regulations for the Development of Novel Drugs: Stringent regulations in countries such as the US, Germany, Japan, and others can pose challenges for drug manufacturers, particularly small and medium-sized enterprises (SMEs), in their efforts to develop and innovate new therapies. The development of drugs involves high costs, extensive clinical trials, and compliance with regulatory requirements, all of which can act as deterrents in investment for research and development. Regulatory bodies such as the FDA in the US and the EMA in Europe oversee the approval process to ensure the safety and efficacy of drugs before they can be marketed and sold for human consumption.

While these regulations serve the purpose of protecting public health, they can also slow down the pace of innovation in drug development. Compliance with these regulations demands significant resources, which can be financially burdensome, particularly for smaller companies, thereby potentially impeding the growth of the Global EZH2 Inhibitors Market in the coming years.

Global EZH2 Inhibitors Market (2023-30): Segmentation Analysis

The Global EZH2 Inhibitors study of MarkNtel Advisors evaluates & highlights the major trends & influencing factors in each segment & includes predictions for the period 2023–2030 at the global, regional, and national levels. Based on the analysis, the market has been further classified as:

Based on Type of Therapy:

• Monotherapy
• Combination Therapy

Combination Therapy of EZH2 inhibitors with other therapeutics like chemotherapy, radiation therapy, etc., is projected to acquire a noteworthy share of the Global EZH2 Inhibitors Market in the future as this approach has shown promising results in both preclinical & clinical trials and would likely become the go-to treatment for cancer patients. By targeting different pathways for cancer progression, companies like Epizyme, Pfizer, etc., are developing drugs for combination therapy to enhance treatment efficacy and reduce overall toxicity levels.

Additionally, combination therapy can help reduce the chances of developing drug resistance to single-agent therapies over time, i.e., a major concern in the field of cancer treatment. Hence, as more research is conducted and new drugs emerge, the use of combination therapy is expected to become more prevalent in the coming years and fuel the demand for EZH2 inhibitors.

Based on Application:

• Epithelioid Sarcoma
• Non-Hodgkin's Lymphoma
• Prostate Cancer
• Breast Cancer
• Lung Cancer
• Others (Ovary, Leukaemia, etc.)

The substantial presence of Lung cancer patients globally has widely accumulated the demand for more effective treatment options for cancer. EZH2 inhibitors are potential therapeutic target drugs in lung cancer owing to their ability to inhibit the activity of the EZH2 protein. According to the World Cancer Research Fund International, over 2.2 million new cancer cases were reported globally in 2020. As the incidence of lung cancer continues to rise due to factors like increased tobacco consumption and rising levels of environmental pollution, the need for EZH2 inhibitors for its treatment will further increase and, in turn, propel the overall market growth in the forecast period.

Global EZH2 Inhibitors Market Regional Projection

Geographically, the Global EZH2 Inhibitors Market expands across:

• North America
• South America
• Europe
• Middle East & Africa
• Asia-Pacific

Of all regions globally, North America would attain considerable growth in the EZH2 Inhibitors Market during 2021-30. It owes to the increasing demand for better healthcare, growing research & development activities for new therapeutic drugs, and the rising prevalence of cancer in the region. As a result, a large number of hospitals & research centers in North America are increasingly adopting EZH2 inhibitor drugs. Furthermore, significant advancements in treatment options to address the growing incidence of cancer in the region, coupled with ongoing clinical trials for the development of effective therapeutic drugs, are other prominent aspects projected to accelerate the regional market growth in the coming years. For instance:

• On 3 April 2023, Eisai agreed with the National Cancer Center to collaborate on investigator-initiated clinical research for the EZH2 inhibitor, 'tazemetostat hydrobromide,' based on the "Patient-Proposed Healthcare Services" system.

Hence, the rapidly rising need for new & more effective cancer therapies, like EZH2 personalized treatment, would spur growth in the North America EZH2 Inhibitors Market over the forecast years.

 Global EZH2 Inhibitors Industry Recent Developments:

• In 2023, Hengrui Pharmaceuticals Co. Ltd. licensed its EZH2 inhibitor, SHR-2554, to Treeline Bioscience in more than a USD700 million deal, in which Treeline would be granted exclusive rights to lymphoma drug worldwide except for greater China.
• In 2022, Daiichi Sankyo launched EZHARMIA®, a dual inhibitor of EZH1 & EZH2, in Japan for the treatment of patients with relapsed or refractory adult T-cell leukemia-lymphoma (ATLL).

Gain a Competitive Edge with Our Global EZH2 Inhibitors Market Report

1. Global EZH2 Inhibitors Market report provides a detailed and thorough analysis of market size, growth rate, competitive landscape, and key players. This comprehensive analysis helps businesses gain a holistic understanding of the market dynamics and make informed decisions.
2. This report also highlights current market trends and future projections, allowing businesses to identify emerging opportunities and potential challenges. By understanding market forecasts, companies can align their strategies and stay ahead of the competition.
3. Global EZH2 Inhibitors Market report aids in assessing and mitigating risks associated with entering or operating in the market.
4. The report would help in understanding market dynamics, regulatory frameworks, and potential challenges, businesses can develop strategies to minimize risks and optimize their operations.